Ultragenyx Pharmaceutical Inc. 0LIF.L Stock
Ultragenyx Pharmaceutical Inc. Price Chart
Ultragenyx Pharmaceutical Inc. 0LIF.L Financial and Trading Overview
Ultragenyx Pharmaceutical Inc. stock price | 38.61 USD |
Previous Close | 51.82 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 65.69 USD |
Volume | 8.5K USD |
Avg. Volume | 223 USD |
Market Cap | 28.83M USD |
Beta (5Y Monthly) | 0.902464 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.874 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0LIF.L Valuation Measures
Enterprise Value | 3.07B USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.07510819 |
Price/Book (mrq) | 15.861486 |
Enterprise Value/Revenue | 7.993 |
Enterprise Value/EBITDA | -4.742 |
Trading Information
Ultragenyx Pharmaceutical Inc. Stock Price History
Beta (5Y Monthly) | 0.902464 |
52-Week Change | -20.12% |
S&P500 52-Week Change | 20.43% |
52 Week High | 65.69 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 45.36 USD |
200-Day Moving Average | 45.97 USD |
0LIF.L Share Statistics
Avg. Volume (3 month) | 223 USD |
Avg. Daily Volume (10-Days) | 118 USD |
Shares Outstanding | 50.58M |
Float | 63.11M |
Short Ratio | N/A |
% Held by Insiders | 4.47% |
% Held by Institutions | 98.17% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -187.31% |
Operating Margin (ttm) | -173.58% |
Gross Margin | -98.70% |
EBITDA Margin | -168.54% |
Management Effectiveness
Return on Assets (ttm) | -30.099% |
Return on Equity (ttm) | -141.42% |
Income Statement
Revenue (ttm) | 383.89M USD |
Revenue Per Share (ttm) | 5.47 USD |
Quarterly Revenue Growth (yoy) | 25.69% |
Gross Profit (ttm) | -370780000 USD |
EBITDA | -647024000 USD |
Net Income Avi to Common (ttm) | -719073024 USD |
Diluted EPS (ttm) | -6.874 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 629.35M USD |
Total Cash Per Share (mrq) | 8.89 USD |
Total Debt (mrq) | 28.6M USD |
Total Debt/Equity (mrq) | 12.97 USD |
Current Ratio (mrq) | 3.512 |
Book Value Per Share (mrq) | 3.121 |
Cash Flow Statement
Operating Cash Flow (ttm) | -419811008 USD |
Levered Free Cash Flow (ttm) | -382491872 USD |
Profile of Ultragenyx Pharmaceutical Inc.
Country | United Kingdom |
State | CA |
City | Novato |
Address | 60 Leveroni Court |
ZIP | 94949 |
Phone | 415 483 8800 |
Website | https://www.ultragenyx.com |
Industry | |
Sector(s) | |
Full Time Employees | 1311 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Q&A For Ultragenyx Pharmaceutical Inc. Stock
What is a current 0LIF.L stock price?
Ultragenyx Pharmaceutical Inc. 0LIF.L stock price today per share is 38.61 USD.
How to purchase Ultragenyx Pharmaceutical Inc. stock?
You can buy 0LIF.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ultragenyx Pharmaceutical Inc.?
The stock symbol or ticker of Ultragenyx Pharmaceutical Inc. is 0LIF.L.
How many shares does Ultragenyx Pharmaceutical Inc. have in circulation?
The max supply of Ultragenyx Pharmaceutical Inc. shares is 582.45K.
What is Ultragenyx Pharmaceutical Inc. Price to Earnings Ratio (PE Ratio)?
Ultragenyx Pharmaceutical Inc. PE Ratio is now.
What was Ultragenyx Pharmaceutical Inc. earnings per share over the trailing 12 months (TTM)?
Ultragenyx Pharmaceutical Inc. EPS is -6.874 USD over the trailing 12 months.